877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Alkaloids, Antineoplastic and immunomodulating drug, Mitotic inhibitors

Categories

Antineoplastic and immunomodulating drugs (1)
Antineoplastic drugs (1)
Pharmaceuticals (1)

Vinflunine (162652-95-1)  
Vinflunine (INN, trade name Javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 - Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States. On November 23, 2007, Pierre Fabre Medicament and Bristol-Myers Squibb announced that they were terminating their license agreement for the development of vinflunine, and that Pierre Fabre were continuing "discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008." As of 2016, vinflunine is the only commercially-approved agent in some countries for salvage therapy of urothelial carcinoma, (with approval based on the results of a phase III trial), with a reported median OS of about 6 months.
Related searches
Alkaloids
Antineoplastic and immunomodulating drug
Mitotic inhibitors